课题基金 / 基金详情

Primary Open Angle African-American Glaucoma Genetics (POAAGG)

Primary Open Angle African-American Glaucoma Genetics (POAAGG)
原发性开角型非裔美国人青光眼遗传学 (POAAGG)
批准号:
8560079
负责人:
JOAN M O'BRIEN
金额:
$226.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-03-01 至 2019-02-28

项目摘要

项目成果

JOAN M O'BRIEN的其他基金

相似基金

相关文献

中文摘要
翻译
POAAGG项目摘要/摘要 青光眼是世界范围内导致不可逆转失明的主要原因,影响大约 7000万人。到2000年,220万美国人被诊断出患有青光眼,而这 预计到2020年,这一数字将达到340万。原发性开角型青光眼(POAG)是一种 与进行性和不可逆性有关的导致视力丧失的疾病谱 视网膜内神经细胞的退化。在亚洲人中,POAG的患病率为3%。 在高加索人中占6%,在70岁及以上的非洲人中占16%。 POAG出现的时间比非裔美国人早了近10年,进展更快 (AAS),使其成为导致该人群不可逆转失明的主要原因。遗传学是 已知在这种疾病中起作用~然而,POAG的遗传学是复杂的,而且有很多风险 这其中涉及到各种因素。这项建议代表了第一个专门针对大规模人口的研究 评估AA的遗传风险因素。 为了检查AAs中的POAG危险因素,全基因组关联研究(GWAS)将 被执行。Gwas是一种在大量人群中检测遗传变异的方法 确定是否有任何变异与某种疾病或特征有关。拟议的全球气候变化网络将 在17,000个AA、2,000个POAG和15,000个对照中生成这些变体的数据。这 实验方法将确定AAS中与POAG相关的基因,这些基因不成比例地 患有更严重的这种疾病。许多不同的临床特征与 POAG,以及对这种诊断的临床决定因素的调查将与基因相关 数据。与在其他人群中探索这种方法的其他机构合作 将用于进一步增强数据集。 除了GWAS,DNA中负责编码蛋白质的部分将是 由于异常蛋白质与疾病易感性有关,因此进行了专门的检查, 进展和严重程度。POAG的遗传风险因素已在其他 人口。这些已知风险因素的相关性,以及新出现的风险因素 从拟议的GWAS调查中,将对非洲裔美国人进行评估。 原发性开角型非裔美国人青光眼遗传学研究的最终目标 (POAAGG)是为了促进开发合理的、有针对性的筛查、诊断和 最终开发出治疗再障POAG的新疗法。
英文摘要
POAAGG Project Summary/Abstract Glaucoma is the leading cause of irreversible blindness worldwide, affecting approximately 70 million people. By 2000, 2.2 million Americans had been diagnosed with glaucoma, and this number is estimated to reach 3.4 million by 2020. Primary open angle glaucoma (POAG) is a spectrum of disease causing vision loss which is associated with progressive and irreversible degeneration of nerve cells in the retina. The prevalence of POAG is 3% among those of Asian ancestry, 6% among Caucasians, and 16% among those of African ancestry age 70 and older. POAG appears almost 10 years earlier and progresses more quickly in African Americans (AAs), making it the leading cause of irreversible blindness in this population. Genetics are known to play a role in this disease~ however, POAG genetics are complex, and many risk factors are involved. This proposal represents the first large population study specifically evaluating AAs for genetic risk factors. In order to examine AAs for POAG risk factors, a genome wide association study (GWAS) will be performed. GWAS is a method that detects genetic variants in a large population to determine if any variants are associated with a disease or trait. The proposed GWAS will generate data on these variants in 17,000 AAs, 2,000 with POAG and 15,000 controls. This experimental approach will identify genes associated with POAG in AAs, who disproportionately suffer from more severe forms of this disease. Many different clinical traits are associated with POAG, and investigation of clinical determinants of this diagnosis will be correlated with genetic data. Collaborations with other institutions that have explored this approach in other populations will be used to further enhance the data set. In addition to the GWAS, the portions of DNA responsible for coding proteins will be specifically examined, since abnormal proteins are associated with disease susceptibility, progression, and severity. Genetic risk factors for POAG have been identified in other populations. The relevance of these known risk factors, along with new risk factors that emerge from the proposed GWAS investigation, will be evaluated for Americans of African ancestry. The ultimate goal of the Primary Open Angle African-American Glaucoma Genetics Study (POAAGG) is to facilitate the development of rational, targeted screening, diagnosis and eventually novel treatments for AA POAG.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Primary Open Angle African-American Glaucoma Genetics Study Renewal
  • 批准号:
    10400065
  • 项目类别:
  • 资助金额:
    $165.32万
  • 财政年份:
    2014
  • 负责人:
    JOAN M O'BRIEN
  • 依托单位:
Primary Open Angle African-American Glaucoma Genetics Study Renewal
  • 批准号:
    10668949
  • 项目类别:
  • 资助金额:
    $142.03万
  • 财政年份:
    2014
  • 负责人:
    JOAN M O'BRIEN
  • 依托单位:
Primary Open Angle African-American Glaucoma Genetics (POAAGG)
  • 批准号:
    8815318
  • 项目类别:
  • 资助金额:
    $221.32万
  • 财政年份:
    2014
  • 负责人:
    JOAN M O'BRIEN
  • 依托单位:
Improved Ophthalmic Care for Retinoblastoma Patients
海外基金